Condition: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal Cancer · Sponsor: AstraZeneca
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Mobile, Alabama, United States | Not Yet Recruiting |
| Research Site | Anchorage, Alaska, United States | Not Yet Recruiting |
| Research Site | Phoenix, Arizona, United States | Not Yet Recruiting |
| Research Site | Springdale, Arkansas, United States | Not Yet Recruiting |
| Research Site | Duarte, California, United States | Not Yet Recruiting |
| Research Site | Fullerton, California, United States | Not Yet Recruiting |
| Research Site | La Jolla, California, United States | Not Yet Recruiting |
| Research Site | Los Alamitos, California, United States | Not Yet Recruiting |
| Research Site | Orange, California, United States | Not Yet Recruiting |
| Research Site | Walnut Creek, California, United States | Not Yet Recruiting |
| Research Site | Denver, Colorado, United States | Not Yet Recruiting |
| Research Site | Lone Tree, Colorado, United States | Not Yet Recruiting |
+ 274 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07431281